Benitec Biopharma Limited

Benitec Limited (ASX:BLT) (PINK:BNIKF) are delighted to announce the appointment of Dr John Chiplin to the Board.

Benitec Limited (ASX:BLT) (PINK:BNIKF) provide an update on progress of one of the pending US continuation patent applications derived from the Graham '099 patent (90/007,247).

ABN Newswire stocks to watch today include: Benitec Limited (ASX:BLT)(PINK:BNIKF), Meteoric Resources NL (ASX:MEI), Magnetic Resources NL (ASX:MAU) and Australian Bauxite Limited (ASX:ABZ).

Benitec Limited (ASX:BLT)(PINK:BNIKF) provide an update on the US patent Ex Parte re-examination on the Graham '099 patent (90/007,247).

The Australian shares edged higher on the first trading day of 2010. Energy stocks surged amid expectations the oil price will continue to rise this year. At the close, the benchmark S&P/ASX200 index advanced 5.7 points, or 0.1 per cent, at 4876.3 points, while the broader All Ordinaries index gained 7.1 points, or 0.1 per cent, to 4889.8.

Benitec Limited (ASX:BLT) (PINK:BNIKF) today announced that it had signed a win-win agreement with Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO).

Benitec Limited (ASX:BLT)(PINK:BNIKF) Chairman Mr Peter Francis Address to Annual General Meeting.

Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) has secured intellectual property rights that underpin its second HIV therapeutic program. This program is a multi-project effort centered at City of Hope to investigate HIV-based vector delivery of anti-HIV RNA (pHIV7-shI-TAR-CCR5RZ) to CD4 T cells as a clinical modality.

The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) are delighted to announce a collaboration with the Children's Cancer Institute Australia for Medical Research (CCIA) for the development of an RNAi therapeutic for lung cancer. Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital.

Benitec Limited (ASX:BLT)(PINK:BNIKF) has now entered into binding agreements with China based Biomics Biotechnologies Co. Ltd. As previously announced, the companies are collaborating on a DNA directed (ddRNAi) or vector expressed RNAi for the treatment of chronic hepatitis B virus (HBV) infection.